MONEAD研究:妊娠及产后早期抗癫痫药物剂量调整策略
本研究基于MONEAD前瞻性观察队列,纳入299例妊娠癫痫女性,分析其妊娠至产后6周的抗癫痫药物剂量调整模式。结果显示多数药物在妊娠期需增量、产后早期需减量,拉莫三嗪和左乙拉西坦的调整幅度最大,这些管理方式与良好发作结局相关。
要点
- 妊娠期67.8%的抗癫痫药物需增量,产后6周内47.9%需减量。
- 拉莫三嗪妊娠期增量中位100 mg/d,分娩时达受孕剂量191%。
- 左乙拉西坦妊娠期增量中位500 mg/d,分娩时达受孕剂量177%。
核心结论
- 妊娠癫痫女性中多数抗癫痫药物需在妊娠期增量、产后早期减量,拉莫三嗪和左乙拉西坦调整幅度最大。
研究设计与样本
- MONEAD为前瞻性观察性队列研究,2012-2016年在美国20个癫痫中心纳入299例妊娠癫痫女性,孕龄<20周,年龄14-45岁。
主要发现
- 妊娠期246/363(67.8%)的抗癫痫药物剂量增加,首次增量中位时间为入组后32天。
- 产后6周内171/357(47.9%)的抗癫痫药物剂量减少,首次减量中位时间为产后3天。
- 拉莫三嗪:128/146(87.7%)增量,中位增量100 mg/d,分娩时平均达受孕剂量191%;产后103/146(70.5%)减量,中位减量100 mg/d,产后6周平均达受孕剂量116%。
- 左乙拉西坦:70/125(56.0%)增量,中位增量500 mg/d,分娩时平均达受孕剂量177%;产后43/125(34.4%)减量,中位减量500 mg/d,产后6周平均达受孕剂量136%。
- 其他抗癫痫药物:10/14增量,8/14产后早期减量。
临床怎么用
- 妊娠期应密切监测抗癫痫药物浓度并及时增量,产后早期需适时减量,尤其拉莫三嗪和左乙拉西坦调整幅度较大。
局限性
- 早孕期数据有限,入组患者来自癫痫中心,使用多种抗癫痫药物的参与者数量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Antiseizure medications (ASMs) undergo marked pharmacokinetic alterations during pregnancy and postpartum. Suboptimal ASM management can lead to adverse maternal and child outcomes. However, there is scant literature to guide how to adjust ASM dosing. This study analyzed how ASMs were dosed in a large observational cohort study of pregnant women with epilepsy (PWWE) who had favorable seizure outcomes. METHODS: Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) was a prospective, observational cohort study that enrolled PWWE 2012-2016 across 20 US epilepsy centers. Inclusion criteria were PWWE, ages 14-45 years, and <20 weeks' gestational age. Seizures and ASM type(s) and doses were documented in a daily diary. Our analysis included ASM doses in pregnancy through early postpartum (6 weeks post-delivery). For each ASM, we analyzed percent participants who underwent ≥1 dose change in pregnancy and postpartum, time of first dose change after enrollment, time to subsequent changes, amount of each dose adjustment, and percent of conception dose at delivery and 6-week postpartum. RESULTS: A total of 299 participants (median 31 [range 17-46] years) were eligible for analysis. Median enrollment was 14-weeks gestation. Dose increases were made in 246/363 (67.8%) of ASMs during pregnancy beginning median 32 days post-enrollment; dose decreases were made within 6 weeks post-delivery for 171/357 (47.9%) of ASMs beginning median 3 days postpartum. For lamotrigine, 128/146 (87.7%) participants had doses increased, by 100 mg/d (median), reaching 191% of conception dose (mean) by delivery. Postpartum, 103/146 (70.5%) had dose tapers, by 100 mg/d (median), to 116% of conception dose (mean) by 6 weeks. For levetiracetam, 70/125 (56.0%) participants had doses increased, by 500 mg/d (median), reaching 177% of conception dose (mean) by delivery. Postpartum, 43/125 (34.4%) had dose tapers, by 500 mg/d (median), to 136% of conception dose (mean) by 6 weeks. For other ASMs, 10/14 had doses increased in pregnancy and 8/14 were tapered early postpartum. DISCUSSION: Previous MONEAD analyses showed no difference in seizure control between pregnant and nonpregnant women with epilepsy. We detail how ASMs were managed in pregnancy and early postpartum to achieve this favorable outcome. These findings can be useful for the management of PWWE. Limitations of this study include limited data in the first trimester, enrollment from epilepsy centers, and limited number of participants on a wider variety of ASMs. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT01730170. Study Details | Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) | ClinicalTrials.gov. First submitted: November 9, 2012. First patient enrolled: December 19, 2012.
引用
- Pennell PB, Li D, Kerr WT, et al. Antiseizure Medication Dosing Strategy During Pregnancy and Early Postpartum in Women With Epilepsy in MONEAD. Neurology. 2025. PMID: 41461064. doi:10.1212/WNL.0000000000214483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。